IVIg Proves Effective for Dermatomyositis in Phase 3 Trial IVIg Proves Effective for Dermatomyositis in Phase 3 Trial
Prior to this trial, intravenous immune globulin had not been fully studied for the treatment of dermatomyositis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 7, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news

IV Immune Globulin Bests Placebo for Dermatomyositis
WEDNESDAY, Oct. 5, 2022 -- Significantly more adults with dermatomyositis receiving intravenous immune globulin (IVIG) versus placebo have a response of at least minimal improvement, according to a study published in the Oct. 6 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2022 Category: Pharmaceuticals Source Type: news

Cutaquig (Immune Globulin Intravenous, Human) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 30, 2022 Category: Drugs & Pharmacology Source Type: news

Panzyga (Immune Globulin Intravenous, human - Ifas Liquid Preparation) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 24, 2022 Category: Drugs & Pharmacology Source Type: news

Octagam (Immune Globulin Intravenous (Human) 5% Liquid Preparation) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 14, 2022 Category: Drugs & Pharmacology Source Type: news

Q & A: What you need to know about monkeypox
Monkeypox burst into the headlines this month after cases were diagnosed in Africa, Europe, North America and Australia.In an interview,Anne Rimoin, the Gordon-Levin Professor of Infectious Diseases and Public Health at the UCLA Fielding School of Public Health, offered insights about the disease, which she has studied for two decades. Rimoin has been director of theUCLA Center for Global and Immigrant Health and is the founder of the UCLA –DRC Health Research and Training Program in the Democratic Republic of the Congo.In simplest terms, what is monkeypox?Monkeypox is a viral zoonosis, a virus that is transmitted from a...
Source: UCLA Newsroom: Health Sciences - May 26, 2022 Category: Universities & Medical Training Source Type: news

Epidemiology of rabies immune globulin use in paediatric and adult patients in the USA: a cross-sectional prevalence study - Burke RV, Russo P, Sicilia M, Wolowich W, Amega N, Nguyen HB.
OBJECTIVES: To compare the epidemiology of paediatric and adult patients receiving rabies immune globulin (RIG). DESIGN: Cross-sectional prevalence study. SETTING: Eligible participants from the Symphony Integrated Dataverse presenting between ... (Source: SafetyLit)
Source: SafetyLit - May 2, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Imogam Rabies (Rabies Immune Globulin (Human)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2022 Category: Drugs & Pharmacology Source Type: news

BayHep B (Hepatitis B Immune Globulin (Human)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2022 Category: Drugs & Pharmacology Source Type: news

Antibody treatment for MIS-C works by depleting inflammatory immune cells
NIH-funded study explains how intravenous immune globulin helps children with rare COVID condition. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - October 15, 2021 Category: American Health Source Type: news

FDA approves Octapharma's Octagam ® 10% for adult dermatomyositis
(Yankee Public Relations) The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam ® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news

FDA Approves Octapharma ’s Octagam 10% for Adult Dermatomyositis
PARAMUS, N.J.--(BUSINESS WIRE) July 20, 2021 --The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2021 Category: Drugs & Pharmacology Source Type: news

New study may offer treatment guidance for MIS-C
(Rutgers University) Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2021 Category: International Medicine & Public Health Source Type: news

Immunomodulation With IVIG, Glucocorticoids Examined in MIS-C
FRIDAY, June 25, 2021 -- The effectiveness of immunomodulation with intravenous immune globulin (IVIG), glucocorticoids, or both varies in multisystem inflammatory syndrome in children (MIS-C), according to results from two observational studies... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 25, 2021 Category: Pharmaceuticals Source Type: news

Study provides MIS-C treatment guidance
(Louisiana State University Health Sciences Center) An analysis conducted by a group of investigators including Tamara Bradford, MD, Associate Professor of Pediatrics at LSU Health New Orleans School of Medicine, found that children and adolescents with Multisystem inflammatory syndrome in children (MIS-C) initially treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 22, 2021 Category: Infectious Diseases Source Type: news